Individuals with sickle cell disease and sickle cell trait demonstrate no increase in mortality or critical illness from COVID-19 - a fifteen hospital observational study in the Bronx, New York

Hoogenboom, Wouter S.; Fleysher, Roman; Soby, Selvin; Mirhaji, Parsa; Mitchell, W. Beau; Morrone, Kerry; Manwani, Deepa; Duong, Timothy Q.

doi:10.3324/haematol.2021.279222

Cited by 42 publications

(49 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Our higher-end hospitalization rate may reflect a conservative approach with our SCD patients. Also notable however, as reported previously [8] , [21] , is that a majority of hospitalizations were for SCD-related rather than COVID-19 related complications, most frequently acute painful episodes. In fact, pediatric patients had no COVID-19 related complications, consistent with previously published milder courses in pediatric SCD patients [3] , [5] , [6] , [9] .…”

Section: Discussionsupporting

confidence: 52%

“…In fact, pediatric patients had no COVID-19 related complications, consistent with previously published milder courses in pediatric SCD patients [3] , [5] , [6] , [9] . Our cohort mortality of 2.5% is on the low end of the 3–10% range in SCD previously reported [1] , [4] , [5] , [21] ; higher than the U.S. general population symptomatic fatality of 1.1% [22] but perhaps not higher when specifically compared to a U.S. black population [4] , [8] . Our in-hospital mortality rate of 3.1% was lower than the 8% found in a nearby geographic area [8] and again, may reflect a conservative approach to hospitalize our SCD patients.…”

Section: Discussionsupporting

confidence: 38%

“…Since COVID-19 infection may precipitate or exacerbate SCD-related complications [8] , [10] , [21] , complications were classified as SCD-related or COVID-19-related as per Table 2 ; outpatients had no complications. Of the 15% (4 of 27) adults who experienced COVID-19 complications, all went to the ICU and required intubation, whereas no children had COVID-19 related complications.…”

Section: Resultsmentioning

confidence: 99%

“…There is equipoise as to whether sickle cell disease (SCD) is a risk factor for disease severity with COVID-19. Some studies support that SCD increases risk for COVID-19 disease severity [1] , [2] , [3] , [4] , [5] , [6] , whereas other studies do not [7] , [8] . Despite possible increased COVID-19 disease severity in SCD, one large study did not show an increased fatality rate in SCD [4] .…”

Section: Introductionmentioning

confidence: 99%

“…Despite possible increased COVID-19 disease severity in SCD, one large study did not show an increased fatality rate in SCD [4] . Patient variables associated with increased clinical severity of COVID-19 infection in SCD patients include older age [1] , [9] , comorbidities [1] , [8] , [9] , [10] , not being on hydroxyurea (HU) [1] , [9] , history of stroke [2] , [8] and black race [5] . Non-SCD studies show similar risk factors such as older age [11] , [12] , comorbidities [11] , [12] , as well as being a health care worker (HCW) [13] , [14] .…”

Section: Introductionmentioning

confidence: 99%

See 4 more Smart Citations

Prognostic factors associated with COVID-19 related severity in sickle cell disease

Yurtsever

Nandi

Ziemba

et al. 2021

Blood Cells, Molecules, and Diseases

View full text Add to dashboard Cite

Section: Discussionsupporting

confidence: 52%

Section: Discussionsupporting

confidence: 38%

Section: Resultsmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

Prognostic factors associated with COVID-19 related severity in sickle cell disease

Yurtsever

Nandi

Ziemba

et al. 2021

Blood Cells, Molecules, and Diseases

View full text Add to dashboard Cite

Hospitalization, Critical Illness, and Mortality Outcomes of COVID‐19 in Patients With Rheumatoid Arthritis

Mehrotra‐Varma,

Kumthekar,

Henry

et al. 2023

ACR Open Rheumatology

Self Cite

View full text Add to dashboard Cite

ObjectiveTo investigate the clinical outcomes of patients with rheumatoid arthritis (RA) with COVID‐19.MethodsThis retrospective study consisted of 361 patients with RA+ and 45,954 patients with RA− (March 2020 to August 2022) who tested positive for SARS‐CoV‐2 by polymerase‐chain‐reaction in the Montefiore Health System, which serves a large low‐income, minority‐predominant population in the Bronx and was an epicenter of the initial pandemic and subsequent surges. Primary outcomes were hospitalization, critical illness, and all‐cause mortality associated with SARS‐CoV‐2 infection. Comparisons were made with and without adjustment for covariates, as well as with 1083 matched controls of patients with RA− and COVID‐19.ResultsPatients with RA+ and COVID‐19 were older (62.2 ± 23.5 vs. 45.5 ± 26.3; P < 0.001), were more likely females (83.1% vs. 55.8%; P < 0.001), were Black (35.5% vs. 30.3%; P < 0.05), and had higher rates of comorbidities (P < 0.05), hospitalization (52.4% vs. 32.5%; P < 0.005), critical illness (10.5% vs. 6.9%; P < 0.05), and mortality (11.1% vs. 6.2%; P < 0.01) compared with patients with RA− and COVID‐19. Patients with RA+ with COVID‐19 had higher odds of critical illness (adjusted odds ratio [aOR] = 1.46, 95% confidence interval [CI]: 1.09‐1.93; P = 0.008) but no differences in hospitalization (aOR = 1.18 [95% CI: 0.93‐1.49]; P = 0.16) and mortality (aOR = 1.34 [95% CI: 0.92‐1.89]; P = 0.10) after adjusting for covariates. Odds ratio analysis identified age, hospitalization status, female sex, chronic kidney disease, chronic obstructive pulmonary disease, and Black race to be significant risk factors for COVID‐19‐related mortality. Pre‐COVID‐19 steroid and biologic therapy to treat RA were not significantly associated with worse outcomes (P > 0.05). Outcomes were not different between patients with RA+ and propensity‐matched RA− controls (P > 0.05).ConclusionOur findings suggest that risk factors for adverse COVID‐19 outcomes were not attributed to RA per se but rather age and preexisting medical conditions of patients with RA.

show abstract

Impact of COVID‐19 on incidence, clinical presentation, and prognosis of acute chest syndrome in patients with sickle cell disease

Dubois,

Virot,

Marie

et al. 2023

eJHaem

View full text Add to dashboard Cite

Acute chest syndrome (ACS) is a frequent complication of sickle cell disease (SCD). Because coronavirus disease 2019 (COVID‐19) increases mortality and morbidity in many diseases, we retrospectively analyzed the impact of SARS‐CoV‐2 infection on the incidence, the clinical presentation, and the prognosis of ACS in patients with SCD by comparing ACS episode before and during COVID‐19 pandemic.Ninety‐nine episodes of ACS were registered over 24 months before pandemic versus 81 episodes over 24 months during the pandemic period. The number of ACS episodes varies among children regarding the two period of time: 26 episodes (26%) for the pre‐pandemic period versus 11 episodes (13%) for the pandemic period (p = 0.03). Comparisons between adults and children showed a higher incidence of initial VOC (45% vs. 24%; p = 0.04) in adults, and a higher incidence of initial pneumonia (35% vs. 15%; p = 0.01) and documented infection (35% vs. 7%; p < 0.001) in children. One patient died during the pandemic period but without any relationship with ACS or COVID‐19. During this pandemic period, 13 episodes of ACS (16%) were found related to coronavirus infection. These ACS episodes did not show any significant differences in terms of outcome when compared to the other ACS episodes observed during this period.Overall, coronavirus infection did not demonstrate a negative impact on incidence, clinical presentation, and outcome of ACS in patients with SCD. Early management, chronic treatment with HU, and exchange transfusions could likely explain the low morbidity and mortality rates.

show abstract

Individuals with sickle cell disease and sickle cell trait demonstrate no increase in mortality or critical illness from COVID-19 - a fifteen hospital observational study in the Bronx, New York

Abstract: Not available.

Cited by 42 publications

References 16 publications

Prognostic factors associated with COVID-19 related severity in sickle cell disease

Prognostic factors associated with COVID-19 related severity in sickle cell disease

Hospitalization, Critical Illness, and Mortality Outcomes of COVID‐19 in Patients With Rheumatoid Arthritis

Impact of COVID‐19 on incidence, clinical presentation, and prognosis of acute chest syndrome in patients with sickle cell disease

Contact Info

Product

Resources

About